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dementia medicines.
Methods: We used Pharmaceutical Benefits Scheme dispensing claims to identify
patients who initiated donepezil, rivastigmine, galantamine or memantine between
1 January 2013 and 30 June 2017 (after a period of ≥180 days with no dispensing
of these medicines) and remained on therapy for ≥180 days (n = 4393), and
dispensed anticholinergic medicines in the 180 days before and after initiating
dementia medicines. We further examined anticholinergic medicines prescribed by
a prescriber other than the one initiating dementia medicines.
Results: One‐third of the study cohort (1439/4393) was exposed to anticholinergic
medicines up to 180 days before or after initiating dementia medicines. Among
patients exposed to anticholinergic medicines, 46% (659/1439) had the same
medicine dispensed before and after initiating dementia medicines. The proportion
of patients dispensed anticholinergic medicines increased by 2.5% (95% confidence
interval [CI]: 1.3–3.7) after initiating dementia medicines. Antipsychotics use increased
by 10.1% (95% CI: 7.6–12.7) after initiating dementia medicines; driven by increased
risperidone use (7.3%, 95% CI: 5.3–9.3). Nearly half of patients dispensed anticholin-
ergic medicines in the 180 days after (537/1133), were prescribed anticholinergic
medicines by a prescriber other than the one initiating dementia medicines.
Conclusion: Use of anticholinergic medicines is common among patients initiating
dementia medicines and this occurs against a backdrop of widespread campaigns to
reduce irrational medicine combinations in this vulnerable population. Decisions about
deprescribing medicines with questionable benefit among patients with dementia
may be complicated by conflicting recommendations in prescribing guidelines.
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1958 NARAYAN ET AL.What is already known about this subject
• Adverse effects of anticholinergic medicines are
exaggerated in older adults with dementia and may
worsen symptoms of dementia.
• Recent campaigns have encouraged clinicians to put
more focus on appropriate use of medicines for older
adults.
What this study adds
• Despite their antagonistic pharmacological effects,
current real‐world evidence shows that 1/3 of patients
initiating dementia medicines were exposed to
anticholinergic medicines up to 180 days before or after.
• There is a myriad of guidelines on managing symptoms of
dementia; however, deprescribing medicines with
questionable benefit among patients with dementia are
complicated by conflicting recommendations, especially
approaches to manage co‐existing morbidities.1 | INTRODUCTION
Nearly 50 million people worldwide are currently living with demen-
tia.1,2 Cholinesterase inhibitors and memantine (dementia medicines)
are the approved pharmacological mainstays and part of the standard
care for managing the symptoms of dementia but they do not reverse
or stop its progression.3,4
Dementia medicines have the potential to cause agitation, insom-
nia and incontinence5 and these unwanted effects might lead to initi-
ation or increased use of anticholinergic medicines.6-9 Additionally,
older adults with dementia are commonly prescribed medicines with
anticholinergic properties to treat comorbidities such as depression,
and anxiety and this further complicates therapy with dementia med-
icines.10 Anticholinergic medicines may cause cognitive impairment,
confusion, loss of concentration and delirium, which are exaggerated
in older adults with dementia.5,11-13 Moreover, use of anticholinergic
medicines may reduce the therapeutic effects of dementia medicines.
A recent population‐based study investigating the effect of high anti-
cholinergic burden after starting cholinesterase inhibitors found that
concomitantly use of anticholinergic medicines had a negative
impacted on the treatment response to cholinesterase inhibitors, lead-
ing to treatment modification, delirium and mortality.14
In an attempt to reduce variation in the management of dementia
and to improve quality of care, best practice guidelines including those
of the National Institute for Health and Care Excellence and American
Psychiatric Association now recommend medicine reviews at the time
of diagnosis to reduced irrational medicine use in patients with
dementia.15-19 These reviews also provide an opportunity to identify
and rule out any reversible cause of confusion such as adverse effects
of other medicines or untreated comorbidities.20 Recommendations
on improving clinical outcomes have been updated; however, deci-
sions on reducing potentially inappropriate combinations of medicines,
such as concomitant use of dementia and anticholinergic medicines
are challenging due to lack of clarity in guidelines for managing comor-
bidities in patients with dementia.16
In Australia, few studies have investigated the use of anticholiner-
gic medicines at the time of initiating dementia therapy.21,22 Most
recently, Gadzhanova and colleagues22 used 2009–2010 dispensing
data to show that approximately 1/3 of patients initiating dementia
medicines are exposed to anticholinergic medicines, in particular, anti-
psychotics.21,22 Since then, guideline recommendations have been
updated to increase awareness of concomitant medicines use and its
impact on the clinical outcomes in patients with dementia and a num-
ber of campaigns such as Choosing Wisely Australia® have encour-
aged clinicians to put more focus on appropriate use of medicines
for older Australians.23 This calls for updated evidence of anticholiner-
gic medicines exposure among patients with dementia to further guide
policy on prescribing practices.
In this study we aimed to provide contemporary real‐world evi-
dence of anticholinergic medicines use among patients initiating
dementia therapy. We examined which anticholinergic medicines were
most commonly dispensed before and after initiating dementia
medicines. We further sought to identify if patients were prescribedanticholinergic medicines by a prescriber other than the one initiating
pharmacological treatment for dementia.2 | METHODS
2.1 | Data source and study setting
In Australia, all citizens and permanent residents are entitled to
subsidised access to prescribed medicines through the Pharmaceutical
Benefits Scheme (PBS). We used anonymised nationwide 10% random
sample of PBS‐eligible people and their dispensing history. This stan-
dard dataset is provided by the Australian Government Department
of Human Services for analytical use and has been previously
described in detail.24 It captures information on all dispensed PBS‐
listed medicines including patient age, sex, date of dispensing, pre-
scriber information and other variables. All medicines are uniquely
identified by item codes and the Anatomical Therapeutic Chemical
(ATC) classification codes. PBS item code provides medicine details
at the product level, including generic name, form, strength, adminis-
tration route, quantity per unit (pack size) and approved indication,
where applicable.24
We extracted data from 1 July 2012 through to 31 December
2017 and examined cholinesterase inhibitors or memantine dispens-
ings from 1 January 2013 to 30 June 2017 (study period).2.2 | Medicines of interest
We included 3 cholinesterase inhibitors subsidised under PBS for the
management of cognitive impairment in patients with mild to moder-
ately severe Alzheimer disease: donepezil (ATC code N06DA02),
NARAYAN ET AL. 1959rivastigmine (ATC code N06DA03) and galantamine (ATC code
N06DA04). We also included memantine (ATC code N06DX01), a
N‐methyl‐d‐aspartate receptor inhibitor which is subsidised for
patients with moderately severe to severe Alzheimer disease.
There is a wide range of medicines with anticholinergic effects. We
limited the selection of these medicines based on a previously pub-
lished list by Kalisch Ellett and colleagues13 who used medicines listed
on the anticholinergic risk scale and the anticholinergic drug scale to
show associations between anticholinergic medicine use and risk of
hospitalisation with confusion or dementia.13 Table S1 lists these
medicines, their ATC codes, therapeutic use and medicine class.TABLE 1 Characteristics of the cohort of patients initiating demen-








Characteristics n = 4393 % n = 1439 % n = 2954 %
Sex
Female 2467 56.2 853 59.3 1614 54.6
Male 1926 43.8 586 40.7 1340 45.4
Age categories (y)
60–64 157 3.6 35 2.4 122 4.12.3 | Study cohort and medicines exposure
Our study comprised all adults in the PBS 10% sample, aged
≥60 years, who were initiated cholinesterase inhibitors or memantine
during the study period and continued dispensings for at least
180 days. We defined initiation of therapy to be the first dementia
medicines dispensing after a period of at least 180 days, during which
no dispensing of any dementia medicines had occurred.
We assumed that the person had remained on therapy for at least
180 days, if they had ≥5 dispensings of their dementia medicines
within 180 days after the date of initiation. We required ≥5 dispens-
ings for donepezil, galantamine and memantine 20‐mg tablets as they
are available in 28‐day pack sizes for once daily dosing and oral formu-
lations of rivastigmine are available in 56‐capsule packs for twice daily
dosing. For memantine 10‐mg tablets, we required only ≥3 dispens-
ings, as the available pack size is 56‐tablet packs and can be used as
once‐daily dosing.25
We defined exposure to anticholinergic medicines before dementia
therapy as any dispensing of an anticholinergic medicine 1–180 days
prior to initiating dementia medicines. We defined exposure to
anticholinergic medicines after initiation of dementia therapy as any dis-
pensing of an anticholinergic within 180 days after initiating dementia
medicines (i.e. including same day dispensings of an anticholinergic
medicine with cholinesterase inhibitors or memantine). Figure S1
demonstrates the selection of the study cohort and their exposure
to medicines with anticholinergic effects from the period 180 days
before and until 180 days after.
65–69 288 6.6 103 7.2 185 6.3
70–74 582 13.3 158 11.0 424 14.4
75–79 997 22.7 329 22.9 668 22.6
80–84 1136 25.6 379 26.3 757 25.6
85–89 925 21.1 317 22.0 608 20.6
90–94 274 6.2 104 7.2 170 5.8
95–99 34 0.8 14 1.0 20 0.7
Dementia medicines initiated
Donepezil 3023 68.8 925 64.3 2098 71.0
Rivastigmine 557 12.7 229 15.9 328 11.1
Galantamine 491 11.2 140 9.7 351 11.9
Memantine 322 7.3 145 10.1 177 6.02.4 | Data analysis
We described the patient characteristics, their exposure to anticholin-
ergic medicines and calculated the number and proportion of patients
exposed to anticholinergic medicines before and after initiating
dementia medicines by medicine class (antidepressants, anti‐
Parkinson's, antipsychotics and other anticholinergic) and specific
medicines. We also estimated the number of patients with anticholin-
ergic medicine dispensings by each 30‐day period up to 180 days
before and 180 days after initiating dementia medicines. We used
the McNemar's test to estimate the difference between the propor-
tion of patients dispensed anticholinergic medicines from before toafter initiation of dementia medicines. Finally, we examined the
proportion of patients prescribed at least 1 anticholinergic medicine
written by a prescriber other than the one who initiated the dementia
medicines.
We used SAS software version 9.4 (SAS Institute Inc., Cary, NC,
USA) and Stata Release 14 (College Station, TX: StataCorp LP) to con-
duct all data analysis.2.5 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY.263 | RESULTS
Our cohort comprised 4393 older adults who initiated dementia
medicines and remained on therapy for at least 180 days. Just over
half (56%) of the cohort were female, 70% were aged between 75
and 89 years and 69% initiated donepezil as their dementia treatment
(Table 1).
One‐third of the study cohort (1439/4393) was exposed to least 1
anticholinergic medicine in the 180 days before or after initiating
dementia medicines. Of those exposed, nearly 2/3 (59%) were dis-
pensed antipsychotic medicines. Risperidone was the most common
1960 NARAYAN ET AL.anticholinergic medicine dispensed (29% of those exposed), followed
by prochlorperazine (18%), amitriptyline (16%), quetiapine (14%) and
oxybutynin (13%).
The proportion of patients exposed to anticholinergic medicines in
each 30‐day period ranged from 9.7 to 10.7% during the 180 days
before initiating dementia medicines and from 13.0 to 13.5% after
initiating dementia medicines (Figure 1).
We observed a 2.5% absolute increase in the number of patients
dispensed anticholinergic medicines after initiating dementia
medicines with the largest increase in the concomitant dispensing of
antipsychotics (10.1%). We found that more patients were dispensed
risperidone and quetiapine after initiating dementia medicines (7.3
and 2.3% respectively) than during the 180 days before such therapy
(Table 2).
Among patients exposed to an anticholinergic medicine, approxi-
mately 1/3 (416/1439) commenced treatment after initiating demen-
tia medicines, while nearly half (659/1439) had the same
anticholinergic medicine dispensed before and after initiating demen-
tia medicines. Risperidone was most commonly dispensed (37.5%)
among those who commenced anticholinergic medicines after initia-
tion of dementia therapy (Table 3), and among those with exposure
to same anticholinergic medicines (22.8%) before and after. (Table S2).
Among patients who were dispensed anticholinergic medicines
after initiating dementia medicines (with or without prior exposure),
we found that nearly half (537/1133) had their anticholinergic
medicines prescribed by a prescriber other than the one who initiated
dementia therapy.4 | DISCUSSION
Dementia is a progressive disease and medicines for dementia might
slow the cognitive decline. Our study provides insight into recentFIGURE 1 Proportion of patients dispensed anticholinergic medicines by
dementia medicinesreal‐world use of medicines for dementia and the prescribing of med-
icines with anticholinergic effects in this population. Current recom-
mendations encourage a medicine review at the time of dementia
diagnosis and thereafter to reduce potentially inappropriate medicine
use, yet we found that anticholinergic medicines were commonly
dispensed to our cohort.
The results of our study mirror the findings of previous studies
conducted almost a decade ago using PBS dispensing data,21,22 sug-
gesting that there has been little change in prescribing practices
among patients dispensed dementia medicines. These results occur
against a backdrop of increasing emphasis on the importance of
evidence‐based practice and calls for improved prescribing in this vul-
nerable population. Our findings are also comparable to international
studies. In a very recent systematic review, Hukins and colleagues
identified anticholinergic medicines as among the most commonly pre-
scribed potentially inappropriate medicines among patients with
dementia, with rates of prescriptions ranging from 6 to 46%.27
There is a myriad of guidelines on managing symptoms of demen-
tia; however, they often lack depth, consistency and/or consensus and
the overall recommendations on managing comorbidities are generally
weak and/or based upon insufficient evidence.28 This leads to
increased challenges for clinicians with ever‐extensive clinical respon-
sibilities and makes it difficult to determine what approach to take. For
instance, concurrent use of anticholinergic medicines is not recom-
mended with cholinesterase inhibitors; however, the primary pharma-
cological management for behavioural and psychological disturbances
in dementia are antipsychotics such as risperidone.15,18,28-32
In our study, the antipsychotic risperidone was the most commonly
dispensed medicine with anticholinergic effects both before and after
initiating dementia medicines. Under PBS restrictions, risperidone for-
mulations are only eligible for government subsidy for managing
behavioural and psychological symptoms of dementia; thus accounting
for the substantial number of dispensings captured in our data.33 Theeach 30‐day interval from 180 days before to 180 days after initiating
TABLE 2 Number and difference in proportions of older adults exposed to anticholinergic medicines 180 days before or 180 days after initiating
dementia medicines by medicine class and the most commonly dispensed anticholinergic medicines
Anticholinergic medicines exposure:
Before initiating dementia medicines After initiating dementia medicines Difference in proportions
n = 1439 n = 1023 % n = 1133 % % CI
Anticholinergic medicine classa
Antidepressants 335 23.3 316 22.0 −1.3 −2.9 to 0.3
Anti‐Parkinson's 25 1.7 26 1.8 0.1 −0.5 to 0.6
Antipsychotics 600 41.7 746 51.8 10.1 7.6 to 12.7
Other anticholinergic medicines 453 31.5 459 31.9 0.4 −2.1 to 2.9
Most common anticholinergic medicines
Risperidone 257 17.9 362 25.2 7.3 5.3 to 9.3
Prochlorperazine 176 12.2 161 11.2 −1.0 −2.9 to 0.8
Amitriptyline 186 12.9 171 11.9 −1.0 −2.4 to 0.3
Quetiapine 161 11.2 194 13.5 2.3 1.2 to 3.4
Oxybutynin 144 10.0 143 9.9 −0.07 −1.3 to 1.2
Olanzapine 115 8.0 124 8.6 0.6 −0.3 to 1.5
Loperamide 74 5.1 89 6.2 1.0 −0.02 to 2.1
Paroxetine 72 5.0 78 5.4 0.4 −0.1 to 1.0
Haloperidol 44 3.1 47 3.3 0.2 −0.7 to 1.1
Carbamazepine 15 1.0 38 2.6 0.3 −0.2 to 0.8
CI, 95% confidence interval.
(%) presented are proportions of all patients in the cohort dispensed an anticholinergic medicine (n = 1439).
This table contains patients who may have received a dispensing of >1 type of anticholinergic medicines during the study period.
aTable S1 outlines the anticholinergic medicine classes.
TABLE 3 Most common anticholinergic medicines commenced by
older adults within 180 days after initiating dementia medicines
Anticholinergic medicines
Patients with new exposure to
anticholinergic medicines











(%) presented are proportions of all patients dispensed anticholinergic
medicines for the first time after initiating dementia medicines (n = 416).
This table contains patients who may have received a dispensing of >1
type of anticholinergic medicine during the study period.
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psychotics such as quetiapine and olanzapine use in patients with
dementia remains uncertain.30,34-36 Clinical trials such as the CATIE‐AD study conclude that adverse effects offset advantages in the effi-
cacy of antipsychotics in the management of psychosis, aggression or
agitation in patients with Alzheimer disease.37
Other anticholinergic medicines commonly co‐dispensed among
our study cohort, such as prochlorperazine, loperamide, oxybutynin
and amitriptyline, may have been used to manage the adverse effects
of dementia medicines, such as nausea, diarrhoea, agitation, insomnia
and incontinence.5 This suggests that the initiation of dementia med-
icines may have led to a prescribing cascade7 and use of medicines
with the potential to worse cognition, among other adverse effects.
This might be most obvious with the prescription of the anticholiner-
gic medicine oxybutynin to manage urinary symptoms that results
from therapy with dementia medicines.11
Patients with dementia experience more comorbidities, may
receive a higher number of medicines and visit multiple prescribers
in comparison to their cognitively intact counterparts, which leads to
fragmentation of care.27,38,39 In our study, we found that nearly half
of the cohort who were co‐prescribed anticholinergic and dementia
medicines visited multiple prescribers. This may have contributed to
polypharmacy and irrational combinations of pro‐cholinergic and
anticholinergic medicines. For example, drug‐interaction software
can only work if both medicines are recorded in the same system,
and prescribers would be familiar with the medicines they choose to
prescribe but might be ignorant of others.
1962 NARAYAN ET AL.Our study has some notable limitations. Medicines with anticholin-
ergic effects have multiple indications and, from our dataset, we could
not determine the reason for which they were prescribed. Thus, we
were unable to confirm for each case, if anticholinergic medicines
use could have been avoided. In addition, we did not have dosing
information and hence could not measure dose reductions of specific
anticholinergic medicines after a patient initiated dementia medicines.5 | CONCLUSION
Anticholinergic medicine use among patients living with dementia
needs further attention from clinicians. Despite high‐quality evidence
of the risks associated with their use, anticholinergic medicines con-
tinue to be commonly dispensed in this vulnerable population. Deci-
sions about the use of medicines with questionable benefit among
patients with dementia are complicated by conflicting recommenda-
tions in prescribing guidelines, especially approaches to manage co‐
existing morbidities. Periodic monitoring such as medicine reviews at
the time of dementia diagnosis and thereafter may help prescribers
identify and reduce potentially inappropriate medicine use and its det-
rimental effects.ACKNOWLEDGEMENTS
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